Puma Biotechnology Inc (NYSE:PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 11:20 a.m. PDT on Wednesday, May 14, at the Bank of America Merrill Lynch 2014 Health Care Conference. The conference will be held at the Encore at the Wynn in Las Vegas. Puma Biotechnology Inc (NYSE:PBYI) stock performance was 5.38% in last session and finished the day at $69.40. Traded volume was 244,111 shares in the last session and the average volume of the stock remained 360.53K shares. Puma Biotechnology Inc (NYSE:PBYI) insider ownership is 19.16%.

J2 Global Inc (NASDAQ:JCOM) released its earnings data on Thursday. The company reported $0.76 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.72 by $0.04, Stock Ratings Network.com reports. The company had revenue of $134.12 million for the quarter, compared to the consensus estimate of $132.06 million. J2 Global Inc (NASDAQ:JCOM) rose 7.53% to $46.96 yesterday on volume of 639,888 shares. The intra-day range of the stock was $44.82 – 47.59. J2 Global Inc (NASDAQ:JCOM) has a market capitalization of $2.23 million.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.54) by $0.15, Analyst Ratings News reports. The company had revenue of $8.30 million for the quarter, compared to the consensus estimate of $10.80 million. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s stock on May 9, 2014 reported a increase 8.10% to the closing price of $54.33. Its fifty two weeks range is $24.56 – 112.57. The total market capitalization recorded $ 3.47 billion. The overall volume in the last trading session was 33,277 shares. In its share capital, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has 63.92 million outstanding shares.

Analysts at Oppenheimer cut their price objective on shares of athenahealth, Inc (NASDAQ:ATHN) from $120.00 to $90.00 in a research report issued to clients and investors on Wednesday, Analyst Ratings.Net reports. The firm currently has an “underperform” rating on the stock. Oppenheimer’s price objective indicates a potential downside of 15.76% from the stock’s previous close. On Friday, shares of athenahealth, Inc (NASDAQ:ATHN) advanced/dropped 768% to close the day at $888. Company return on investment (ROI) is 56.677% and its monthly performance is recorded as 60.88%. athenahealth, Inc (NASDAQ:ATHN) quarterly revenue growth is 878%.